We protect our product candidates through the use of patents, trade secrets and careful monitoring of our proprietary know-how. Our patent portfolios are wholly owned by us. They include issued patents or patent applications that claim deuterated analogs of nearly 100 non-deuterated drugs and drug candidates.
The U.S. Patent and Trademark Office (USPTO) has issued 114 patents relating to Concert’s DCE Platform. Additionally, our patent portfolio includes numerous issued foreign patents including issuances in Europe, Japan, China, Australia, and Russia, among other territories.
To learn more about Concert’s U.S. issued patents visit the USPTO website
In April 2017, Incyte filed an Inter Partes Review Petition (IPR) against Concert seeking to invalidate Concert’s US Patent No. 9,249,149. In April 2019, the PTAB issued a final written decision in connection with the IPR. While PTAB found that the claims of the ‘149 patent are not patentable, the IPR decision is appealable to the U.S. Court of Appeals for the Federal Circuit, and Concert remains committed to defending the ‘149 patent. The ‘149 patent remains valid and enforceable until appeals have been exhausted.
Copies of the petitions and responses during the Federal Circuit Appeal follow below.
Copies of the petitions and responses during the PTAB proceeding follow below.